구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Temozolomide, Surgery, Radiotherapy (Temozolomide, Surgery, Radiotherapy) Activartis Biotech·Glioblastoma Multiforme 30 trials |
|---|---|
Overview Program | Temozolomide, Surgery, Radiotherapy |
Overview Company | Activartis Biotech |
Overview Modality | CGT |
Overview Target | Glioblastoma Multiforme |
Overview Indication | Glioblastoma Multiforme |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Efficacy and safety of tumor-treating fields combined with concurrent chemoradiotherapy for newly diagnosed glioblastoma patients.. Tumour treating fields (TTFields) have demonstrated efficacy in extending survival in the temozolomide maintenance therapy phase. Consequently, the purpose of this study is to investigate the safety and efficacy of TTFields in combination with concurrent chemoradiothe… |
Clinical Safety signal | Efficacy and safety of tumor-treating fields combined with concurrent chemoradiotherapy for newly diagnosed glioblastoma patients.. Tumour treating fields (TTFields) have demonstrated efficacy in extending survival in the temozolomide maintenance therapy phase. Consequently, the purpose of this study is to investigate the safety and efficacy of TTFields in combination with concurrent chemoradiothe… |
Clinical Result source | ClinicalTrials.gov NCT02052648 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT02052648 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Temozolomide, Surgery, Radiotherapy (Temozolomide, Surgery, Radiotherapy) Activartis Biotech·Glioblastoma Multiforme 30 trials |
|---|---|
Overview Program | Temozolomide, Surgery, Radiotherapy |
Overview Company | Activartis Biotech |
Overview Modality | CGT |
Overview Target | Glioblastoma Multiforme |
Overview Indication | Glioblastoma Multiforme |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Efficacy and safety of tumor-treating fields combined with concurrent chemoradiotherapy for newly diagnosed glioblastoma patients.. Tumour treating fields (TTFields) have demonstrated efficacy in extending survival in the temozolomide maintenance therapy phase. Consequently, the purpose of this study is to investigate the safety and efficacy of TTFields in combination with concurrent chemoradiothe… |
Clinical Safety signal | Efficacy and safety of tumor-treating fields combined with concurrent chemoradiotherapy for newly diagnosed glioblastoma patients.. Tumour treating fields (TTFields) have demonstrated efficacy in extending survival in the temozolomide maintenance therapy phase. Consequently, the purpose of this study is to investigate the safety and efficacy of TTFields in combination with concurrent chemoradiothe… |
Clinical Result source | ClinicalTrials.gov NCT02052648 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT02052648 |
추천 비교
추천 비교